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The fungal pathogen Candida albicans is frequently associated with catheter-based infections because of its ability to
form resilient biofilms. Prior studies have shown that the transcription factor Bcr1 governs biofilm formation in an in
vitro catheter model. However, the mechanistic role of the Bcr1 pathway and its relationship to biofilm formation in
vivo are unknown. Our studies of biofilm formation in vitro indicate that the surface protein Als3, a known adhesin, is a
key target under Bcr1 control. We show that an als3/als3 mutant is biofilm-defective in vitro, and that ALS3
overexpression rescues the biofilm defect of the bcr1/bcr1 mutant. We extend these findings with an in vivo venous
catheter model. The bcr1/bcr1 mutant is unable to populate the catheter surface, though its virulence suggests that it
has no growth defect in vivo. ALS3 overexpression rescues the bcr1/bcr1 biofilm defect in vivo, thus arguing that Als3 is
a pivotal Bcr1 target in this setting. Surprisingly, the als3/als3 mutant forms a biofilm in vivo, and we suggest that
additional Bcr1 targets compensate for the Als3 defect in vivo. Indeed, overexpression of Bcr1 targets ALS1, ECE1, and
HWP1 partially restores biofilm formation in a bcr1/bcr1 mutant background in vitro, though these genes are not
required for biofilm formation in vitro. Our findings demonstrate that the Bcr1 pathway functions in vivo to promote
biofilm formation, and that Als3-mediated adherence is a fundamental property under Bcr1 control. Known adhesins
Als1 and Hwp1 also contribute to biofilm formation, as does the novel protein Ece1.
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Introduction
Bioﬁlms are microbial communities that are associated
with solid surfaces. Most bacteria and fungi exist predom-
inantly in such communities in nature, and they form the
basis for numerous interactions that affect human health.
Cells in a bioﬁlm display phenotypes that are distinct from
their free-living counterparts, including extreme resistance
to many antimicrobial agents [1–4]. Their health impact is
reﬂected in the fact that implanted medical devices, such as
intravascular catheters, are major risk factors for blood-
stream and deep tissue infection [5, 6]. These devices serve as
substrates for bioﬁlm development; the mass and intrinsic
drug resistance of the bioﬁlm limits efﬁcacy of host defenses
and antimicrobial therapy. These bioﬁlm-based infections
are estimated to cause about 50% of all nosocomial
infections [5, 7].
The fungal pathogen Candida albicans is a major cause of
device-associated infections [5, 8, 9]. It produces adherent
bioﬁlms on a variety of different surfaces in vitro [3, 4, 10, 11].
Bioﬁlm formation begins with surface adherence of yeast-
form cells, which grow to yield a basal layer. Basal layer cells
include some hyphae, or long tubular chains of cells, which
extend to yield an upper layer that is almost exclusively
hyphae. As the bioﬁlm matures, it produces an extracellular
matrix containing predominantly carbohydrate and protein
[1, 12, 13].
C. albicans Bcr1, a C2H2 zinc ﬁnger protein, has a signiﬁcant
role in bioﬁlm formation: bcr1/bcr1 insertion and deletion
mutants form only rudimentary bioﬁlms on silicone catheter
material in vitro [14]. Bcr1 is required for expression of
several cell wall protein genes, and we have proposed that
Bcr1 is a positive regulator of adherence. Many Bcr1 target
genes had been identiﬁed initially as hyphal-speciﬁc genes,
and BCR1 RNA accumulation depends upon the hyphal
developmental activator Tec1 [14]. Bcr1 is not required for
hyphal morphogenesis, and we believe that it acts down-
stream of Tec1 to activate the acquisition of hyphal
adherence properties.
Bioﬁlms are considerably more complex in vivo than in
vitro. For example, in vivo, bioﬁlms form on intravascular
catheters under conditions of vascular ﬂow, and are exposed
to and incorporate many plasma constituents. The complex-
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question of whether the same mechanisms are required for
bioﬁlm formation in vitro as in vivo. Indeed, several fungal
and bacterial mutants have medium-dependent bioﬁlm
defects in vitro [15, 16]. Thus, the functions of key regulators
must be appraised in vivo in order to connect questions in
developmental biology to answers in antimicrobial therapy.
Recently developed animal models permit analysis of C.
albicans bioﬁlm formation in vivo. Central venous catheter
infection models have been described for both rabbits [17]
and rats [18]. These catheter surfaces are substrates for
extensive bioﬁlm formation, and bioﬁlm cells on these
substrates exhibit reduced antifungal susceptibility. These
models further reﬂect the circumstances of human infection,
in that the bioﬁlm cells can lead to seeding and infection of
organs [18].
In this report, we test the roles of Bcr1 target genes in
bioﬁlm formation in vitro. Our ﬁndings substantiate the
proposal that Bcr1 is a regulator of adherence. We extend this
analysis to an in vivo model, where our ﬁndings argue that
adherence is a fundamental property under Bcr1 control that
promotes bioﬁlm formation and that the adhesin Als3 is a
pivotal functional target of Bcr1 both in vitro and in vivo.
Our ﬁndings highlight the complexity of in vivo bioﬁlm
formation, yet reveal a convergence of in vitro and in vivo
studies to deﬁne a signiﬁcant bioﬁlm regulatory mechanism.
Results
Bcr1 Promotes Adherence In Vitro
We proposed that Bcr1 acts in the hyphal development
pathway to promote adherence through stimulation of
expression of several cell surface protein genes. This
hypothesis predicts that overexpression of BCR1 in yeast
form cells may stimulate adherence. We tested this prediction
by examining the effects of BCR1 expression in a tec1/tec1
mutant (Figures 1 and 2), which is defective in producing
hyphae in vitro [19]. The tec1/tec1 mutant is defective in
bioﬁlm formation [14], and the mutant cells fail to adhere to
silicone catheter material (Figures 1A, 1C, and 2, Strain Set
A). Introduction of a TEF1-BCR1 overexpression construct
restored bioﬁlm formation ability partially to the tec1/tec1
mutant (Figures 1F and 2, Strain Set A; p ¼ 0.018 for the
comparison of biomass determinations). Overexpression of
BCR1 in the tec1/tec1 mutant does not restore hyphal
formation ability (Figure 1G–1I). We believe that the partial
suppression by TEF1-BCR1 reﬂects the failure to restore
hyphal formation to the tec1/tec1 mutant. In any case, these
ﬁndings support the idea that Bcr1 is a positive regulator of
adherence, but not of hyphal formation.
To understand the mechanism of Bcr1-promoted adher-
ence, we compared expression of Bcr1-dependent genes in
strains with or without the TEF1-BCR1 construct (Figure 3).
The genes HYR1, HWP1, CHT2, ECE1, RBT5, ALS1, and ALS3
were expressed at much lower levels in a bcr1/bcr1 mutant than
in the wild-type reference strain (Figure 3, samples 3 and 7).
The presence of the TEF1-BCR1 construct restored expres-
sion of these genes and bioﬁlm formation in the bcr1/bcr1
mutant, thus verifying the function of the construct (Figure 2;
Figure 3, samples 2 and 7). The surface protein gene ECM331
was expressed at higher levels in the bcr1/bcr1 mutant than in
the wild-type reference strain, and this elevated expression
was also reversed by the TEF1-BCR1 construct (Figure 3,
samples 2, 3, and 7). We note that TEF1-BCR1 did not
substantially increase expression of Bcr1-dependent genes in
the otherwise wild-type reference strain background (Figure
3, samples 5 and 3). Among the Bcr1-dependent genes, we
found that HYR1, HWP1, CHT2, ECE1, and ALS3 were
expressed at reduced levels in the tec1/tec1 strain compared
to the reference strain (Figure 3, samples 3 and 6).
Introduction of the TEF1-BCR1 construct increased expres-
sion of these genes in the tec1/tec1 strain (Figure 3, samples 4
and 6). These ﬁndings suggest that Bcr1 acts downstream of
Tec1 to activate expression of target genes HYR1, HWP1,
CHT2, ECE1, and ALS3. Furthermore, the augmented adher-
ence during bioﬁlm formation of the tec1/tec1 TEF1-BCR1
strain highlights this particular group of Bcr1-dependent
g e n e sa sc a n d i d a t e sf o rm e d i a t o r so fB c r 1 - d e p e n d e n t
adherence.
Key Role of Bcr1 Target Gene ALS3 in Biofilm Formation In
Vitro
To test the roles of Bcr1 target genes in bioﬁlm formation,
we carried out bioﬁlm formation assays with mutants
defective in each gene. We observed no signiﬁcant bioﬁlm
defect in hyr1/hyr1 (p¼0.463), ece1/ece1 (p¼0.850), cht2/cht2 (p¼
0.909), or rbt5/rbt5 (p ¼ 0.323) mutant strains versus the
reference strain (Figure 2, Strain Set B; Figure 4). The als1/als1
and hwp1/hwp1 mutants also produced substantial bioﬁlms
(Figure 4), although the bioﬁlms often sloughed off the
substrate. Bioﬁlm biomass determinations further indicated
that the hwp1/hwp1 mutant has a partial bioﬁlm defect
compared to the reference strain (Figure 2, Strain Set B, p
¼0.022). In contrast to the als1/als1 and hwp1/hwp1 strains, the
als3/als3 mutant displayed a severe defect in bioﬁlm for-
mation compared to the reference strain (Figure 2, Strain Set
B; Figure 4; p ¼ 0.005), and introduction of a single wild-type
ALS3 allele rescued the defect substantially (Figure 2, Strain
Set B; p¼0.005). Confocal scanning laser microscopy (CSLM)
imaging revealed that the als3/als3 mutant formed a rudi-
mentary bioﬁlm of 20 lm in depth, while the wild-type and
als3/als3þpALS3 complemented strains produced bioﬁlms of
over 200 lm in depth (Figure 5). CSLM depth images showed
that the rudimentary als3/als3 mutant bioﬁlm was comprised
mainly of yeast cells, with few hyphae, whereas the bioﬁlms of
the wild-type and als3/als3 þ pALS3 complemented strains
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Synopsis
The formation of biofilms (surface-attached microbial communities)
on implanted medical devices such as catheters is a major cause of
fungal and bacterial infections. Prior studies of the fungal pathogen
Candida albicans have shown that the regulator Bcr1 is required for
biofilm formation in vitro, but the mechanism through which it
promotes biofilm formation and its significance for biofilm
formation in vivo was uncertain. The authors demonstrate that
Bcr1 is required for biofilm formation in vivo in a rat model of
catheter-based infection. Manipulation of Bcr1 target genes through
mutation and gene overexpression shows that the known surface
adhesin Als3 has a pivotal role in biofilm formation and that
adhesins Als1 and Hwp1 also contribute to biofilm formation. The
results thus indicate that adherence is the key property regulated by
Bcr1 and highlight a group of adhesins as potential therapeutic
targets.included abundant hyphae (Figure 5). It should be noted that
the als3/als3 mutant is not defective in hyphal formation as it
forms normal hyphae when assayed under hyphal inducing
conditions (Figure 5). Hyphae are also apparent among the
cells in the surrounding medium of an als3/als3 mutant
bioﬁlm (unpublished data). These ﬁndings argue that Als3 has
a major role in bioﬁlm formation and suggest that reduced
expression of ALS3 in the bcr1/bcr1 mutant may account for its
bioﬁlm defect.
If reduced expression of ALS3 is the cause of the bcr1/bcr1
mutant bioﬁlm defect, then increased expression of ALS3 in a
bcr1/bcr1 mutant background should promote bioﬁlm for-
mation. To test this prediction, we introduced the TEF1
promoter adjacent to the native ALS3 coding region to create
a TEF1-ALS3 allele, permitting Bcr1-independent ALS3
expression. RT-PCR measurement of ALS3 RNA levels
conﬁrmed that the TEF1-ALS3 allele permits expression of
ALS3 in both BCR1/BCR1 and bcr1/bcr1 backgrounds (Figure
6). In the wild-type reference strain background, TEF1-ALS3
had no obvious effect on bioﬁlm formation (Figure 6, top
row). In the bcr1/bcr1 mutant background, TEF1-ALS3 im-
proved bioﬁlm formation substantially (Figure 2; Figure 6,
top row; p ¼ 0.002). These observations indicate that
increased ALS3 expression in the bcr1/bcr1 mutant promotes
signiﬁcant bioﬁlm formation ability.
We used CSLM imaging to examine the structure of
bioﬁlms that resulted from increased ALS3 expression. The
TEF1-ALS3 allele did not alter bioﬁlm structure in the
otherwise wild-type background (Figure 6, CSLM depth and
side views): bioﬁlm depth was about 400 lm; little staining
occurred in the basal region; and hyphal staining was
prominent. The bcr1/bcr1 strain produced a thin rudimentary
bioﬁlm comprised largely of yeast form cells, as expected [14].
The bcr1/bcr1 TEF1-ALS3 strain produced a substantial bioﬁlm
that included a basal poorly stained region (Figure 6), similar
in appearance to those of the wild-type strain (Figure 6) and
complemented bcr1/bcr1 mutant [14]. Thus, increased ALS3
expression permits at least partial rescue of the bcr1/bcr1
mutant defect in bioﬁlm formation.
Bcr1 Function in Biofilm Formation In Vivo
In order to determine whether Bcr1 may have a role in
bioﬁlm formation in vivo, we turned to a rat venous catheter
model [18]. Implanted catheters were allowed to stabilize for
24 h and were then inoculated with wild-type, bcr1/bcr1
mutant, or bcr1/bcr1 þ pBCR1 complemented strains. Bioﬁlm
formation was visualized after 12, 24, and 48 h by scanning
Figure 1. Effect of Increased BCR1 Expression on Adherence and Hyphal Morphogenesis
Strains were grown under in vitro biofilm assay conditions for 60 h and photographed (A–F) or grown in Spider suspension cultures and examined by
phase contrast microscopy at 3400 magnification (G–I). For the biofilms assays, turbid medium with all cells free-floating in the medium rather than
attached to the silicone substrate indicates a biofilm-negative phenotype; clear medium with the silicone substrate completely covered with cells
indicates a biofilm-positive phenotype. Relevant genotypes are given above each panel for strains CJN1015 (reference strain þ TEF1) (A, G), CJN1060
(bcr1/bcr1þTEF1) (B), CJN1052 (tec1/tec1þTEF1) (C, H), CJN1039 (reference strainþTEF1-BCR1) (D), CJN1011 (bcr1/bcr1þTEF1-BCR1) (E), and CJN1035
(tec1/tec1 þ TEF1-BCR1) (F, I).
DOI: 10.1371/journal.ppat.0020063.g001
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(Figure 7). The wild-type and bcr1/bcr1 þ pBCR1 comple-
mented strains initiated bioﬁlm formation by 12 h and
yielded extensive adherent populations by 24 h (Figure 7A,
7B, 7G, and 7H). Both strains produced mature bioﬁlms by 48
h that included abundant matrix material (Figure 7C and 7I),
as previously reported for strain K1 [18]. In contrast, the bcr1/
bcr1 mutant yielded few adherent cells at 12 and 24 h (Figure
7D and 7E), and the catheter surface was devoid of bioﬁlm
material after 48 h (Figure 7F). Despite the dramatic differ-
ences in bioﬁlm formation ability, the three strains grew
comparably in a mouse disseminated infection model;
median mouse survival time was 13 d after inoculation with
the wild-type strain and 10 d after inoculation with either the
bcr1/bcr1 mutant or bcr1/bcr1 þ pBCR1 complemented strains.
Based on this evidence, Bcr1 is not required for growth in
vivo under non–bioﬁlm-forming conditions but is required
for bioﬁlm formation in vivo.
Als3 Function in Biofilm Formation In Vivo
Our observations above indicate that Als3 is a key mediator
of Bcr1-dependent bioﬁlm formation in vitro. To verify that
these ﬁndings extend to in vivo bioﬁlm formation, we
compared als3/als3 mutant and als3/als3 þ pALS3 comple-
mented strains in the rat venous catheter model. Both strains
formed extensive bioﬁlms within 24 h (Figure 8A and 8B).
Therefore, Als3 is not absolutely required for bioﬁlm
formation in vivo.
To determine whether Als3 may contribute to bioﬁlm
formation in vivo, we tested the ability of the TEF1-ALS3
expression construct to rescue the bcr1/bcr1 mutant bioﬁlm
defect. The bcr1/bcr1 TEF1-ALS3 strain produced an extensive
bioﬁlm containing both cells and matrix material (Figure 8C).
This bioﬁlm, formed after 24 h, was similar in overall
appearance to that formed by the BCR1/BCR1 control strains
(Figures 7B and 8B). TEF1-ALS3 expression thus rescues
bioﬁlm formation in a bcr1/bcr1 background (compare Figures
7E and 8C). These ﬁndings support the model that ALS3 is a
critical Bcr1 target gene that functions in bioﬁlm formation
in vivo.
Overexpression Assays of Bcr1 Target Gene Function In
Vitro
Our in vivo assays suggest that Als3 may be one of several
Bcr1 targets that contribute to bioﬁlm formation. The
analysis of insertion and deletion mutant strains above
pointed toward Als1 and Hwp1 as additional candidate
functional targets, although their bioﬁlm defects were mild:
bioﬁlm biomass was reduced only slightly (Figure 2), and
CSLM visualization revealed no qualitative defects (unpub-
lished data). Thus, we turned to an alternative functional
analysis strategy, gene overexpression, which has recently
been applied with considerable success on a genome-wide
scale in Saccharomyces cerevisiae [20]. Gene overexpression is
particularly useful in identifying functions among partially
redundant genes, the situation that we postulate to exist here.
To determine if increased expression of Bcr1-activated
target genes, other than ALS3, may rescue the bioﬁlm defect
of the bcr1/bcr1 mutant, we created genomic fusions of the
TEF1 promoter to the CHT2, HYR1, RBT5, ALS1, HWP1, and
ECE1 coding regions. The TEF1-ALS1, TEF1-HWP1, and TEF1-
ECE1 alleles improved bioﬁlm formation ability considerably
(p , 0.004 for all comparisons to bcr1/bcr1), although not to
the extent of TEF1-ALS3 (Figure 2, Strain Set C; p , 0.006 for
Figure 2. Biofilm Dry Mass Determinations
Biofilm dry mass determinations were made in quadruplicate after 60 h growth under standard biofilm conditions, as detailed in Materials and Methods.
Reference strains DAY185 (shown) and CAI4-URA3 (not shown) gave similar results. Strains are grouped for convenience of comparison. Strain Set A
contains CJN896 (tec1/tec1), CJN1052 (tec1/tec1 þ TEF1), CJN1035 (tec1/tec1 þ TEF1-BCR1), CJN1023 (tec1/tec1 þ pTEC1), CJN702 (bcr1/bcr1), CJN1060
(bcr1/bcr1 þ TEF1), CJN1011 (bcr1/bcr1 þ TEF1-BCR1), CJN698 (bcr1/bcr1 þ pBCR1), respectively. Strain Set B contains FJS2 (hyr1/hyr1), FJS6 (ece1/ece1),
FJS5 (cht2/cht2), FJS8 (rbt5/rbt5), CAYC2YF1U (als1/als1), CAH7-1A1E2 (hwp1/hwp1), CAYF178U (als3/als3), CAQTP178U (als3/als3þpALS3), respectively.
Strain Set C contains CJN1153 (bcr1/bcr1 þ TEF1-ALS3), CJN1144 (bcr1/bcr1 þ TEF1-ALS1), CJN1288 (bcr1/bcr1 þ TEF1-ECE1), CJN1222 (bcr1/bcr1 þ TEF1-
HWP1), CJN1281 (bcr1/bcr1 þ TEF1-CHT2), CJN1259 (bcr1/bcr1 þ TEF1-HYR1), CJN1276 (bcr1/bcr1 þ TEF1-RBT5), respectively.
DOI: 10.1371/journal.ppat.0020063.g002
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promoter fusion alleles did not augment bioﬁlm formation in
the BCR1/BCR1 background (unpublished data). These results
indicate that Als1, Hwp1, and Ece1 may act in addition to
Als3 to contribute to bioﬁlm formation.
Discussion
We have recently taken a genetic approach to elucidate the
mechanistic basis of C. albicans bioﬁlm formation [14, 15]. A
central issue is how in vitro bioﬁlm models are related to
bioﬁlm growth in vivo and, thus, to disease. Here we have
shown that the transcription factor Bcr1 is required in vivo,
as it is in vitro, for bioﬁlm formation. One key target gene
under Bcr1 control is ALS3, as demonstrated by the rescue of
bioﬁlm formation through increased ALS3 expression in vitro
and in vivo. These results argue that Als3-mediated adher-
ence is a key factor in formation of bioﬁlms in vitro and in
vivo. However, absence of Als3 causes a bioﬁlm defect only in
vitro and not in vivo. One implication from this result is that
Bcr1 activates additional bioﬁlm adhesin genes. In support of
this model, we ﬁnd that overexpression of three additional
Bcr1 target genes partially restores bioﬁlm formation ability
in vitro to a bcr1/bcr1 mutant. Our ﬁndings are summarized in
Figure 9. Clearly, the interplay of in vitro and in vivo analyses
holds great promise for deﬁning bioﬁlm regulatory mecha-
nisms.
Relationship of Bcr1 and Hyphal Gene Expression
Our studies here solidify the concept that Bcr1 relays a
signal within the hyphal developmental program because an
increase in BCR1 expression leads to increased expression of
the hyphal-speciﬁc genes HYR1, HWP1, and ALS3 in a hyphal-
defective tec1/tec1 mutant. However, we ﬁnd that some Bcr1-
dependent genes are expressed substantially in the tec1/tec1
strain, including RBT5, ECE1, and ALS1, despite the reduced
expression of BCR1. Two simple explanations can account for
this apparent paradox. One possibility is that the 4-fold
reduced level of Bcr1 in the tec1/tec1 mutant is sufﬁcient to
activate a subset of target genes. These genes may have the
highest-afﬁnity Bcr1 binding sites, or their promoter regions
may include binding sites for additional transcription factors
that interact cooperatively with Bcr1. A second possibility is
that some Bcr1 target genes are subject to a compensatory
regulatory mechanism in the tec1/tec1 background. The latter
explanation seems particularly plausible for RBT5, which
responds to numerous genetic and environmental regulatory
Figure 3. Effect of Increased BCR1 Expression on Target Gene RNA Levels
RNA prepared from mid-log phase Spider medium cultures was used to prepare Northern blots or in RT-PCR assays, as indicated. Northern blots were
probed for the transcripts indicated along the left side, and PhosphorImager exposures are shown. RT-PCR assays for ALS1, ALS3, and TEF1 were
conducted on serial 2-fold dilutions of cDNA preparations and fractionated on agarose gels; only the last two dilutions are shown. TEF1 transcript levels
were used as an expression control. Strains included DAY185 (reference strain) (sample 1), CJN1011 (bcr1/bcr1 þ TEF1-BCR1) (sample 2), CJN1015
(reference strainþTEF1) (sample 3), CJN1035 (tec1/tec1þTEF1-BCR1) (sample 4), CJN1039 (reference strainþTEF1-BCR1) (sample 5), CJN1052 (tec1/tec1þ
TEF1) (sample 6), and CJN1060 (bcr1/bcr1 þ TEF1) (sample 7).
DOI: 10.1371/journal.ppat.0020063.g003
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help to distinguish between these explanations.
One unexpected observation is that CHT2 expression is
both Bcr1 and Tec1 dependent. CHT2, which speciﬁes a cell
wall chitinase homolog, is expressed at higher levels in yeast
cells than hyphal cells under many growth conditions [24, 25].
However, CHT2 is not exclusively a yeast phase-speciﬁc gene.
For example, it was found to be coregulated with numerous
hyphal-speciﬁc genes in a study of pH-regulated gene
expression [26], and the CHT2 transcript has been detected
previously in cells induced to form hyphae in Spider medium
or serum [21]. Our results indicate that Bcr1 and Tec1 target
genes are not restricted to hyphal-speciﬁc genes.
Control of Adherence by Bcr1 during Biofilm Formation In
Vitro
The proposal that Bcr1 is a positive regulator of bioﬁlm
adherence stems from two prior observations. First, Bcr1 is
required for bioﬁlm formation, a process that depends upon
both cell-cell and cell-substrate adherence. Second, numerous
Bcr1-dependent genes encode proteins that contribute to cell
wall or cell surface structure. The in vitro studies reported
here include three lines of evidence in support of this
proposal. First, expression of Bcr1 in a tec1/tec1 mutant
promotes substantial adherence to a silicone substrate.
Second, a deletion of one Bcr1-dependent adhesin gene,
ALS3, causes a bioﬁlm formation defect similar to that of the
bcr1/bcr1 mutant. Third, the bcr1/bcr1 bioﬁlm formation defect
is fully rescued through increased expression of Als3 and
partially rescued through increased expression of two other
known adhesins, Als1 and Hwp1. Our results thus indicate
that the adhesin expression defect is a major cause of the bcr1/
bcr1 mutant bioﬁlm formation defect.
The tec1/tec1 mutant has a severe bioﬁlm defect: it grows
under our in vitro cultivation conditions as a suspension of
yeast cells. Introduction of TEF1-BCR1 alters that mutant
phenotype by promoting growth primarily on the surface of
the silicone substrate. The bioﬁlm so formed is unstable in
that it disperses into clumps of cells during manipulation,
and its biomass is 3-fold less than that of the wild-type and
complemented mutant strains. Thus, expression of Bcr1 is
not sufﬁcient to promote extensive bioﬁlm formation by
yeast cells. However, increased adherence of the tec1/tec1
Figure 4. Biofilm Formation In Vitro by Bcr1 Target Gene Mutants
Strains were grown in our standard biofilm assay and photographed after 60 h. Relevant genotypes are given above each panel and include DAY286
(reference strain), CJN459 (bcr1/bcr1), FJS2 (hyr1/hyr1), CAH7-1A1E2 (hwp1/hwp1), FJS5 (cht2/cht2), FJS6 (ece1/ece1), FJS8 (rbt5/rbt5), FJS10 (ecm331/
ecm331), CAYF178U (als3/als3), and CAYC2YF1U (als1/als1). Turbid medium with all cells free-floating in the medium rather than attached to the silicone
substrate indicates a biofilm-negative phenotype; clear medium with the silicone substrate completely covered with cells indicates a biofilm-positive
phenotype. An uninoculated control is shown in the panel labeled ‘‘Blank.’’
DOI: 10.1371/journal.ppat.0020063.g004
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apparent, thus connecting Bcr1 function to adherence.
The ﬁnding that the Bcr1-dependent adhesin Als3 is
required for bioﬁlm formation strengthens this connection.
Als3 belongs to a large C. albicans protein family with
structural features similar to those of the a mating agglutinin
of S. cerevisiae [27, 28]. Direct assays have demonstrated roles
for C. albicans Als1, Als3, Als5, and Als6 in adherence to
diverse substrates [29], and mutational analysis indicates that
Als2 and Als4 are also adhesins [30]. The two Bcr1-dependent
family members, Als1 and Als3, have highly related sequences
throughout their N-terminal domains, the region implicated
in substrate binding. This close relationship is reﬂected by
their similar substrate binding properties [29]. Our studies
here also support a close functional relationship between
Als1 and Als3, because overexpression of either adhesin in a
bcr1/bcr1 background restores bioﬁlm formation to a meas-
urable extent. There are some functional distinctions
between Als1 and Als3, because Als3 is required for bioﬁlm
formation under our in vitro assay conditions, while Als1 is
not. Similarly, TEF1-ALS3 is more efﬁcient than TEF1-ALS1 in
suppression of the bcr1/bcr1 bioﬁlm defect. Nonetheless, the
clear connection between Bcr1, Als1, and Als3 argues that a
major functional role of Bcr1 is to promote adherence.
One unexpected conclusion from our ﬁndings is that Hwp1
contributes to bioﬁlm formation in vitro. Hwp1 is a well-
characterized hyphal adhesin that serves as a substrate for
mammalian transglutaminases, thus mediating covalent at-
tachment of C. albicans to host cells [28, 31]. It has not
previously been shown to mediate interactions between C.
albicans cells, and the transglutaminases that modify Hwp1 are
of mammalian origin [31]. Our observations suggest that
Hwp1 can mediate C. albicans cell-cell interactions, and that it
does so in the absence of transglutaminase activity. An
interesting implication is that Hwp1 may contribute to
adherence between mating partners, thus explaining its up-
regulation by mating factor [32, 33].
Our ﬁndings also implicate Ece1 in adhesion, thus
providing the ﬁrst functional insight into this protein. ECE1
was discovered as a hyphal-induced gene and was among the
ﬁrst C. albicans genes disrupted with the Ura-blaster method
[34, 35]. However, the ece1/ece1 mutant has no apparent
phenotypic defect [35]. The idea that Ece1 functions in
adhesion is suggested by our observation that its over-
expression restores bioﬁlm formation to a bcr1/bcr1 mutant.
ECE1, like HWP1, is induced by mating pheromone [33],
another possible connection between Ece1 and adherence.
Ece1 does not resemble an adhesin: it is comprised of novel
34-residue repeats that surround a possible transmembrane
domain [35]. Although its mechanism of action is uncertain,
an interesting possibility is that Ece1 promotes surface
exposure of adhesins.
Genetic Control of Biofilm Formation In Vivo
Bioﬁlm formation in vivo is considerably more complex
than in vitro and involves dynamic interactions with many
host proteins, cells, and environmental factors. These differ-
ences raise the question of whether the major genetic factors
operative in vitro play a commensurate role in vivo. We have
addressed this issue for two gene products: Bcr1 and Als3.
Although the experimental outcomes were different in detail,
they argue that both proteins have signiﬁcant roles in vivo.
The signiﬁcance of Bcr1 is clearest: it is required in vivo for
bioﬁlm formation but not for growth. The fact that the
mutant leaves catheter surfaces essentially clear of material
suggests that there is a defect in early events of bioﬁlm
formation in vivo, much as observed in vitro. The defects
under the two circumstances, however, are slightly different:
a thin layer of bcr1/bcr1 mutant cells is associated with the
substrate transiently in vivo but stably in vitro. It is possible
that the few substrate-bound cells that appear early in vivo
may be destroyed later by host defenses. An alternative
possibility is that larger cell masses are dislodged efﬁciently
by blood ﬂow if their adherence is compromised by the bcr1
defect. In either case, it is clear that Bcr1 governs a
mechanism that contributes to bioﬁlm formation in vivo.
The potency of TEF1-ALS3 as a suppressor of the bcr1/bcr1
defect argues that Als3 also has a critical role in bioﬁlm
formation in vivo. How can that observation be reconciled
Figure 5. In Vitro Filamentation and Biofilm Formation by the als3/als3
Mutant
Cells were grown in free-living (planktonic) cultures in Spider medium;
filamentation was examined by phase contrast microscopy at 3400
magnification (top panels). Biofilms were grown under standard
conditions in Spider medium, and stained with concanavalin A conjugate
for CSLM visualization. Artificially colored CSLM depth views, in which
blue color represents cells closest to the silicone and red color represents
cells farthest from the silicone, are shown in middle panels. For the depth
views of reference strain CAI4-URA3 (ALS3/ALS3), blue¼ 0 lm and red ¼
800 lm; CAYF178U (als3/als3), blue ¼ 0 lm, red ¼ 80 lm; CAQTP178U
(als3/als3 þ pALS3), blue ¼ 0 lm, red ¼ 600 lm. CSLM side views are
shown in lower panels. For the side views, the scale bars represent 50 lm
for CAI4-URA3 (ALS3/ALS3) and CAQTP178U (als3/als3 þ pALS3); and 20
lm for CAYF178U (als3/als3).
DOI: 10.1371/journal.ppat.0020063.g005
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Critical C. albicans Biofilm Adhesinswith the fact that an als3/als3 null mutant has no bioﬁlm
defect in vivo? One simple model is that additional adhesins
can partially compensate for the absence of Als3 in vivo but
not in vitro. Our overexpression studies implicate Als1 and
Hwp1 as candidate compensatory adhesins, in keeping with
this model. The distinction between the in vivo and in vitro
situations may reﬂect a higher level of expression of the
compensatory adhesins in vivo than in vitro. A second
possibility is that host constituents, for example serum
components, may contribute to adherence. Thus, the same
low level of surface adhesin activity may support bioﬁlm
formation in vivo but not in vitro.
The restoration of bioﬁlm formation through ALS3 over-
expression in the bcr1/bcr1 mutant both in vitro and in vivo
indicates that Bcr1 governs one main function relevant for
bioﬁlm formation: adherence. Although transcription factor
mutants are useful for deﬁnition of functionally related
genes, the mechanistic basis for their phenotypic defects can
be complex because of the extent of their gene expression
defects. Moreover, functional overlap among targets can
obscure loss-of-function target gene mutant phenotypes. Our
results here illustrate the utility of gene overexpression for
identiﬁcation of critical target genes that govern a complex
process.
Figure 6. Overexpression of ALS3 in the bcr1/bcr1 Mutant Restores Substantial Biofilm Formation In Vitro
Biofilms were grown under standard conditions and stained with concanavalin A conjugate for CSLM visualization. The top panels show the visual
appearance. The next set of panels show depth views, in which blue color represents cells closest to the silicone and red color represents cells farthest
from the silicone. The next set of panels show side views. For the depth views of reference strain DAY185 (BCR1/BCR1), blue¼0 lm and red¼600 lm;
CJN1149 (BCR1/BCR1þTEF1-ALS3), blue¼0 lm and red¼500 lm; CJN702 (bcr1/bcr1), blue¼0 lm and red¼80 lm; CJN1153 (bcr1/bcr1þTEF1-ALS3),
blue ¼ 0 lm and red ¼ 180 lm. For the side views, the scale bars represent 50 lm for DAY185 (BCR1/BCR1), CJN1149 (BCR1/BCR1 þ TEF1-ALS3), and
CJN1153 (bcr1/bcr1 þ TEF1-ALS3); and 20 lm for CJN702 (bcr1/bcr1). The next set of panels show RT-PCR analysis of ALS3 expression of the indicated
strains with successive 2-fold dilutions of cDNA from left to right. The bottom panels show RT-PCR of control TEF1 transcript levels.
DOI: 10.1371/journal.ppat.0020063.g006
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Media. C. albicans strains were grown at 30 8C in either YPD (2%
Bacto Peptone, 2% dextrose,1% yeast extract) for Uraþ strains or in
YPDþuri (2% Bacto Peptone, 2% dextrose,1% yeast extract, and 80
lg/ml uridine) for Ura  strains. C. albicans transformants were
selected for on synthetic medium (2% dextrose, 6.7% YNB with
ammonium sulfate, and auxotrophic supplements) or on YPDþclon-
NAT (2% Bacto Peptone, 2% dextrose,1% yeast extract, and 400 lg/
ml clonNAT [WERNER BioAgents, Jena, Germany]) for Natþ strains.
For bioﬁlm growth, strains were grown at 37 8C in Spider medium
[36]. Assays for hyphal induction of the tec1/tec1 mutant (þ vector)
(CJN1052), the tec1/tec1 mutant overexpressing BCR1 (CJN1035), the
reference strain (þ vector) (CJN1015), the reference strain (DAY185),
the als3/als3 mutant (CAYF178U), and the als3/als3 þpALS3 comple-
mented strain (CAQTP178U) were also done at 37 8C in Spider
medium.
Plasmid and C. albicans strain construction. All strains used in this
study are listed in Table 1. All strains are derived from BWP17
(ura3D::kimm434/ura3D::kimm434 arg4::hisG/arg4::hisG his1::hisG/his1::
hisG) [37] except for the following CAI4 derivatives [34]: CAI4-
URA3 [38], CAYC2YF1U, the als1/als1 mutant strain [39], and CAH7-
1A1E2 [28], the hwp1/hwp1 mutant strain. Construction of the bcr1/bcr1
insertion mutant strain, CJN459; the tec1/tec1 insertion mutant strain,
CJN308; the bcr1/bcr1 deletion mutant strain, CJN702, and its
complemented strain, CJN698, was described previously [14].
For construction of the insertion mutant strains for Bcr1 target
genes, we took advantage of a Tn7-UAU1 plasmid insertion mutant
library containing our genes of interest, made by The Institute for
Genome Research (TIGR). Each TIGR plasmid containing the orf::Tn7-
Figure 7. Bcr1 Requirement for Biofilm Formation In Vivo
Central venous catheters were introduced into rats, inoculated with C. albicans strain DAY185 (BCR1/BCR1) (A–C), CJN 702 (bcr1/bcr1) (D–F), or CJN698
(bcr1/bcr1 þ pBCR1) (G–I) and then flushed and incubated [18]. Catheters were the removed and their contents visualized by scanning electron
microscopy after 12 h (A, D, G), 24 h (B, E, H), and 48 h (C, F, I).
DOI: 10.1371/journal.ppat.0020063.g007
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Critical C. albicans Biofilm AdhesinsUAU1 segment for orf19.4975 (HYR1), orf19.3895 (CHT2), orf19.3374
(ECE1), orf19.5636 (RBT5), and orf19.4255 (ECM331) was released by
NotI digestion and then transformed into strain BWP17 using
standard C. albicans transformation protocols described previously
[40], except that C. albicans cells were heat shocked at 44 8C for 20 min,
which increased efﬁciency, instead of the standard 42 8C for 1 h. The
Argþ heterozygous transformants were then used to obtain Argþ
Uraþhomozygous insertion mutant strains FJS2 (hyr1/hyr1), FJS5 (cht2/
cht2), FJS6 (ece1/ece1), FJS8 (rbt5/rbt5), and FJS10 (ecm331/ecm331) using
methods described previously [40]. These homozygous insertion
mutants were then screened by colony PCR to ensure absence of
the wild-type allele. We used strain DAY286 (ArgþUraþHis ) [40] as
a reference strain for these mutants.
For construction of the TEF1-BCR1 overexpression plasmid
pCJN491, PCR was done using primers OE723-ATG (59-ATGTCAGG
GACATCACAAGTACTTCA-39) and OE723-908 (59-AATAA
TAGTTTCCCAATTGAAAAAAGAGAGGAC-39) to generate a
2,723-bp fragment beginning from the ATG of the BCR1 ORF
(orf19.8342) to 500 bp downstream of the stop codon. This fragment
was inserted into the pGEMT-Easy vector (Promega, Madison,
Wisconsin, United States) and then digested with EcoRI and SpeI
(releasing a 1,650-bp fragment containing the larger portion of the
BCR1 ORF including the start codon and 1,650 bp downstream of the
start codon), and cloned into an EcoRI- and SpeI-linearized vector
pTEF1 [15], to yield plasmid pCJN491 in the correct orientation.
pTEF1 [15] is a vector that harbors the constitutively active TEF1
promoter that is derived from pDDB78, a HIS1 vector [41]. A unique
SbfI site lying within the 1,650-bp portion of BCR1 was used to direct
integration of the plasmid to the natural BCR1 locus via SbfI
digestion. The TEF1-BCR1 overexpression C. albicans strains CJN1011,
CJN1035, and CJN1039 were constructed by transforming CJN459 (a
His  bcr1/bcr1 insertion mutant), CJN308 (a His  tec1/tec1 insertion
mutant), and DAY286 (a His  reference strain), respectively, with
SbfI-linearized pCJN491 to generate Hisþ strains overexpressing
BCR1. The TEF1 vector alone C. albicans strains CJN1060, CJN1052,
and CJN1015 were constructed by transforming CJN459, CJN308, and
DAY286, respectively, with NruI-linearized pTEF1 to generate Hisþ
strains with the vector alone.
The NAT1-TEF1 overexpression plasmid pCJN498 was generated as
follows. PCR was done using primers AgNat1F (59-AT
CAAGCTTGCCTCGTCC-39)a n dA g N a t 1 R( 5 9-GCGTTAGTATC
GAATCGACAG-39) with the template plasmid pJK799 [42] to
generate a 1,220-bp fragment amplifying the Ashbya gossypii TEF1
promoter next to the C. albicans NAT1 ORF and followed by the A.
gossypii TEF1 terminator. The use of A. gossypii sequences instead of C.
albicans sequences in pJK799 surrounding the NAT1 ORF prevents
misintegration of the construct [42]. This fragment was inserted into
the pGEMT-Easy vector (Promega) in the correct orientation to
create plasmid pCJN495. PCR was done using primers TEF1-SpeIF
(59-AAACTAGTGCATCTAAACATCAATTGAC-39) and TEF1-Nde1R
(59-GATTGATCATATGTATATAAAATGTATACTTAG-39) to gener-
ate an 800-bp product containing the C. albicans TEF1 promoter with
Figure 8. Role of Als3 in Biofilm Formation In Vivo
Central venous catheters were introduced into rats, inoculated with C. albicans strains CAYF178U (als3/als3) (A), CAQTP178U (als3/als3þpALS3) (B), or
CJN1153 (bcr1/bcr1þTEF1-ALS3) (C), and then flushed and incubated for 24 h [18]. Catheters were subsequently removed and their contents visualized
by scanning electron microscopy.
DOI: 10.1371/journal.ppat.0020063.g008
Figure 9. Role of Bcr1 Target Genes in Biofilm Formation
Bcr1 is required for full expression of adhesins Als3, Als1, and Hwp1 and
of novel protein Ece1. Gene mutation and overexpression analyses
together prove that Als3 is necessary and sufficient among Bcr1 targets
for biofilm formation in vitro. Overexpression analysis indicates that Als1,
Hwp1, and Ece1 can also restore biofilm formation in the absence of Bcr1
in vitro. The fact that overexpression suppressors Als3, Als1, and Hwp1
are all known adhesins indicates that adherence is the property through
which Bcr1 governs biofilm formation. Bcr1 is required for biofilm
formation in vivo, and overexpression of Als3 permits biofilm formation
in the absence of Bcr1 in vivo. Thus, Bcr1-dependent adherence is critical
for biofilm formation in vivo and in vitro.
DOI: 10.1371/journal.ppat.0020063.g009
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Critical C. albicans Biofilm AdhesinsTable 1. C. albicans Strains Used in This Study
Strain Genotype Reference
BWP17 ura3D::kimm434 arg4::hisG his1::hisG [37]
ura3D::kimm434 arg4::hisG his1::hisG
CAH7-1A1E2 ura3D::kimm434 hwp1::hisG eno1::URA3 [28]
ura3D::kimm434 hwp1::hisG ENO1
CAI4 ura3D::kimm434 [34]
ura3D::kimm434
CAI4-URA3 ura3D::kimm434 ARG4::pARG4-URA3 [38]
ura3D::kimm434 ARG4
CAYF178U ura3D::kimm434::URA3-IRO1 als3::ARG4 arg4::hisG his1::hisG This study
ura3D::kimm434 als3::HIS1 arg4::hisG his1::hisG
CAQTP178U ura3D::kimm434::URA3-IRO1 als3::ARG4::ALS3 arg4::hisG his1::hisG This study
ura3D::kimm434 als3::HIS1 arg4::hisG his1::hisG
CAYC2YF1U ura3D::kimm434::URA3-IRO1 als1::hisG [39]
ura3D::kimm434 als1::hisG
CJN308 ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-UAU1 [14]
ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-URA3
CJN459 ura3D::kimm434 arg4::hisG his1::hisG bcr1::Tn7-UAU1 [14]
ura3D::kimm434 arg4::hisG his1::hisG bcr1::Tn7-URA3
CJN698 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1-BCR1 bcr1::ARG4 [14]
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3
CJN702 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 [14]
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3
CJN896 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 tec1::Tn7-UAU1 [14]
ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-URA3
CJN1011 ura3D::kimm434 arg4::hisG his1::hisG bcr1::Tn7-UAU1::pHIS1-TEF1-BCR1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::Tn7-URA3
CJN1015 ura3D::kimm434 ARG4:URA3::arg4::hisG his1::hisG::pHIS1-TEF1 This study
ura3D::kimm434 arg4::hisG his1::hisG
CJN1023 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1-TEC1 tec1::Tn7-UAU1 [14]
ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-URA3
CJN1035 ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-UAU1 BCR1::pHIS1-TEF1-BCR1 This study
ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-URA3 BCR1
CJN1039 ura3D::kimm434 ARG4:URA3::arg4::hisG his1::hisG BCR1::pHIS1-TEF1-BCR1 This study
ura3D::kimm434 arg4::hisG his1::hisG BCR1
CJN1052 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1-TEF1 tec1::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG tec1::Tn7-URA3
CJN1060 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1-TEF1 bcr1::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::Tn7-URA3
CJN1144 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-ALS1::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 ALS1
CJN1149 ura3D::kimm434 ARG4:URA3::arg4::hisG his1::hisG::pHIS1 TEF1-ALS3::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG ALS3
CJN1153 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-ALS3::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 ALS3
CJN1222 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-HWP1::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 HWP1
CJN1259 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-HYR1::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 HYR1
CJN1276 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-RBT5::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 RBT5
CJN1281 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-CHT2::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 CHT2
CJN1288 ura3D::kimm434 arg4::hisG his1::hisG::pHIS1 bcr1::ARG4 TEF1-ECE1::NAT1 This study
ura3D::kimm434 arg4::hisG his1::hisG bcr1::URA3 ECE1
DAY185 ura3D::kimm434 ARG4:URA3::arg4::hisG his1::hisG::pHIS1 [43]
ura3D::kimm434 arg4::hisG his1::hisG
DAY286 ura3D::kimm434 ARG4:URA3::arg4::hisG his1::hisG [40]
ura3D::kimm434 arg4::hisG his1::hisG
FJS2 ura3D::kimm434 arg4::hisG his1::hisG hyr1::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG hyr1::Tn7-URA3
FJS5 ura3D::kimm434 arg4::hisG his1::hisG cht2::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG cht2::Tn7-URA3
FJS6 ura3D::kimm434 arg4::hisG his1::hisG ece1::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG ece1::Tn7-URA3
FJS8 ura3D::kimm434 arg4::hisG his1::hisG rbt5::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG rbt5::Tn7-URA3
FJS10 ura3D::kimm434 arg4::hisG his1::hisG ecm331::Tn7-UAU1 This study
ura3D::kimm434 arg4::hisG his1::hisG ecm331::Tn7-URA3
DOI: 10.1371/journal.ppat.0020063.t001
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the promoter, respectively. This PCR fragment was digested with
NdeI and SpeI and ligated into NdeI- and SpeI-digested plasmid
pCJN495 to create pCJN498 containing the A. gossypii TEF1 promoter
next to the C. albicans NAT1 ORF, followed by the A. gossypii TEF1
terminator, followed by the C. albicans TEF1 promoter in the correct
orientation.
The TEF1-ALS3 overexpression C. albicans strains CJN1149 and
CJN1153 were constructed by transforming DAY185 (a Hisþ
reference strain) [43] and CJN702 (a Hisþ bcr1/bcr1 deletion mutant),
respectively, using PCR products from template plasmid pCJN498
and primers ALS3-F-OE-Ag-NAT-Ag-TEF1p (59-AGCCAAA
CAATCCGAAGCAACGTAAAGTACGATATCAAAGAATCATAACT
TTGCTTTCTATTTGATAACCCGCCTCAAATCAAGATTGGGAGG
TTAACAATCAAGCTTGCCTCGTCCCC-39) and ALS3-R-OE-Ag-
NAT-Ag-TEF1p (59-TAGACCAAGTCAATGAATTAAAACTGTT
GAAAACACCAGTGATTGTCTTTGCAGTCGCAACCGACAAATA
TATGAGTAACAATGTATATTGTTGTAGCATTATAAAATGTAT
ACTTAGAA-39). These primers amplify the entire A. gossypii TEF1
promoter, the C. albicans NAT1 ORF, the A. gossypii TEF1 terminator,
and the C. albicans TEF1 promoter with 100 bp of hanging homology
to 500 bp upstream into the promoter of ALS3 for the forward
primer and 100 bp of hanging homology from exactly the start codon
of the ALS3 ORF. The homology in these primers allows for
homologous recombination of the entire cassette directly upstream
of the ALS3 natural locus so that ALS3 can be overexpressed with the
TEF1 promoter instead of its natural promoter. The transformation
into C. albicans strains was done as described above except an
additional 5-h recovery step in YPD at 30 8C was done after the cells
were heat shocked at 44 8C for 20 min in order to allow for NAT1
expression. The cells were then plated onto YPDþ400 lg/ml clonNat
plates for 2 d at 30 8C to select for Natþ transformants, and
transformants were checked by colony PCR. We used strain DAY185
(Argþ Uraþ Hisþ) [43] as a reference strain for these strains.
The als3D/als3D mutant, CAYF178U, was constructed from strain
BWP17. The two alleles of ALS3 were serially disrupted using the
markers HIS1 and ARG4. The disruption cassettes were ampliﬁed
with the following primers: ALS3-5DR (59-CCTCATTACACCAAC
CATACAACTTTGTGGTCTACAACTTGGGTTATTGAAACAAAAA
CAGTTTTCCCAGTCACGACGTT-39)a n dA L S 3 - 3 D R( 5 9-
GGTTGATTCAGCAGTAGTAGTAACAGTAGTAGTTTCATCAGC
ACTAGAAGAAATGATAGGTGTGGAATTGTGAGCGGATA-39).
The disruption of ALS3 was veriﬁed by PCR using the following
primers: 3Conﬁrm-1 (59-ATGACACCATGTCAAGTTCAGA-39)
and 3Conﬁrm-2 (59-GTTGGTTGTTCAATGACACTGG-39). To
complement the als3D/als3D mutant with a wild-type copy of
ALS3, a full–length version of ALS3 was digested from pGEMT
with PvuI and SphI [29], and then subcloned into pDS10 at the
SphI site [44]. The construct was linearized with Bsp1407I and
integrated into the ALS3 locus of the als3D/als3D Ura  strain,
selecting Uraþ.E x c i s i o no ft h eURA3-dpl200 marker was then
selected by plating on 5-FOA medium. ALS3 complementation
was conﬁrmed by PCR using primers 59-TGAAGCAGCCTT
TAGTGGCCT-39 and 59-AGAAGTGGAAGCAGCTGTGGA-39.
URA3 and the adjacent IRO1 locus was restored in the als1D/als1D
strain [39], als3D/als3D, and als3D/als3D::ALS3 strains as follows. Ura 
derivatives of these mutants were selected by plating on synthetic
media containing 5-FOA and uridine. A 3.9-kb URA3-IRO1 fragment
was released from pBSK-URA3 by NotI/PstI digestion and used to
transform the Ura strains [44]. The restoration of URA3 to its native
locus was conﬁrmed by PCR using the primers 59-
TGCTGGTTGGAAT GCTTATTTG-39 and 59-TGCAAATTCTGC
TACTGGAGTT-39.
In vitro bioﬁlm growth conditions. For in vitro bioﬁlm growth
assays, strains were grown in YPD overnight at 30 8C, diluted to an
OD600 ¼ 0.5 in 2 ml of Spider medium (with auxotrophic
supplements), and added to a sterile 12-well plate with a prepared
silicone square (1.5 3 1.5 cm cut from Cardiovascular Instrument
silicone sheets [Wakeﬁled, Massachusetts, United States]). The
silicone square was previously treated with bovine serum (B-9433;
Sigma, St. Louis, Missouri, United States) overnight and washed with
PBS in order to prepare it for the bioﬁlm assay. The inoculated
plate was incubated at 37 8C for 90 min at 150 rpm agitation for
initial adhesion of cells. To remove unadhered cells, the squares
were washed with 2 ml of PBS, and the squares were moved to a
fresh 12-well plate containing 2 ml of fresh Spider medium. This
plate was incubated at 37 8C for an additional 60 h at 150-rpm
agitation to allow for bioﬁlm formation.
Microscopic visualization of in vitro bioﬁlms. For the in vitro
experiments, bioﬁlms were observed visually and by CSLM. For in
vitro CSLM imaging, bioﬁlms were stained with 25 lg/ml con-
canavalin A Alexa Fluor 594 conjugate (C-11253; Molecular Probes,
Eugene, Oregon, United States) for 1 h in the dark at 37 8C with 150
rpm agitation. CSLM was performed with an upright Zeiss
Axioskop2 FS MOT LSM 510 multiphoton microscope using a Zeiss
Achroplan 340/0.8W objective. In order to visualize concanavalin A
conjugate staining, a HeNe1 laser with 543-nm excitation wave-
length was used. All in vitro CSLM images were assembled into side
and depth views using the Zeiss LSM Image Browser (version
3.2.0.115) software. For all side views, the silicone is located at the
top of the image. Depth views are artiﬁcially colored images
indicating cell depth using a color gradient, where blue represents
cells closest to and red represents cells farthest from the silicone
substrate.
RNA isolation and expression analysis. Overnight cultures were
inoculated in 5 ml of YPD at 30 8C. The next day, 100 ml of Spider
medium was inoculated with the YPD overnight culture to obtain an
OD600 ¼ 0.05, and was grown at 37 8C for 12 h (OD600 ¼ ’8). Cells
were immediately harvested by vacuum ﬁltration. RNA extraction
and Northern analysis were performed as previously described [40].
For RT-PCR analysis for detection of ALS1 and ALS3,1 0lg of total
RNA was DNase treated at 37 8C for 1 h, ethanol precipitated, and
resuspended in 100 ll of DEPC water. cDNA was synthesized and
RT-PCR was done as previously described for ALS1 and ALS3 [45]
with reverse transcriptase and without reverse transcriptase (as a
control).
In vivo bioﬁlm model. A rat central venous catheter infection
model [18] was selected for in vivo bioﬁlm studies. The catheter
diameter was chosen in an attempt to permit blood ﬂow around the
extraluminal catheter surface. To mimic material used in patients,
polyethylene tubing (inner diameter  0.76 mm, outer diameter 1.52
mm) was chosen. Speciﬁc-pathogen-free Sprague-Dawley rats
weighing 400 g were used (Harlan Sprague-Dawley, Indianapolis,
Indiana, United States). A heparinized (100 U/ml) catheter was
surgically inserted into the external jugular vein and advanced to a
site above the right atrium (2 cm length). The catheter was secured
to the vein and the proximal end tunneled subcutaneously to the
midscapular space and externalized through the skin. The catheters
were placed 24 h prior to infection to allow a conditioning period
for deposition of host protein on the catheter surface. Infection was
achieved by intraluminal instillation of 500 llo fC. albicans cells (10
6
cells/ml). After a dwelling period of 4 h, the catheter volume was
withdrawn and the catheter was ﬂushed with heparinized 0.15 M
NaCl.
Catheters from two animals were removed at three time points (12,
24, and 48 h) after C. albicans infection to determine bioﬁlm
development on the internal surface of the intravascular devices.
The distal 2 cm of the catheter was cut from the entire catheter
length, and bioﬁlms were imaged using both CSLM and scanning
electron microscopy. Scanning electron microscopy was used for
architectural investigation of the bioﬁlm process. Catheter segments
were washed with 0.1 M phosphate buffer (pH 7.2) and placed in
ﬁxative (1% glutaraldehyde and 4% formaldehyde). The samples were
then washed with buffer for 5 min and placed in 1% osmium
tetroxide for 30 min. The samples were then dehydrated in a series of
10-min ethanol washes (30%, 50%, 70%, 85%, 95%, and 100%). Final
desiccation was accomplished by critical point drying (Tousimis,
Rockville, Maryland, United States). Specimens were mounted on
aluminum stubs and sputter-coated with gold. Samples were imaged
in a scanning electron microscope (Hitachi S-5700 or JEOL JSM-
6100) in the high-vacuum mode at 10 kV. The images were processed
for display using Adobe Photoshop 7.0.1.
Disseminated murine candidiasis models. Groups of ten 20-g male
Balb/C mice were inoculated via the lateral tail vein with 5 3 10
5
blastospores with each strain of C. albicans. The mice were monitored
three times daily for survival.
Bioﬁlm dry mass measurements. For dry mass measurements, each
silicone square was weighed prior to inoculation with the strain of
interest. Bioﬁlms were grown for 60 h on the silicone square (as
described above). The silicone squares containing their respective
bioﬁlms were then removed from the wells, dried overnight in a fume
hood, and weighed the following day. Total biomass of each bioﬁlm
was calculated by subtracting the weight of the silicone prior to
bioﬁlm growth from the weight of the silicone after bioﬁlm growth.
The average total biomass for each strain was calculated from four
independent samples after subtracting the mass of a blank silicone
square with no cells added. Statistical signiﬁcance (p-values) was
calculated with the Student’s two-tailed t-test function in Microsoft
Excel.
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Figure S1. Mouse Survival Data
Disseminated murine candidiasis assays. Groups of ten 20-g male
Balb/C mice were inoculated via the lateral tail vein with 5 3 10
5
blastospores with each strain of C. albicans. The mice were monitored
three times daily for survival.
Found at DOI: 10.1371/journal.ppat.0020063.sg001 (44 KB PDF).
Accession Numbers
Information for the following C. albicans genes can be found at the
Candida Genome Database (CGD) Web site (http://www.
candidagenome.org): BCR1 (orf19.723), TEC1 (orf19.5908), HWP1
(orf19.1321), ALS3 (orf19.1816), ALS1 (orf19.5741), HYR1 (orf19.4975),
CHT2 (orf19.3895), ECE1 (orf19.3374), RBT5 (orf19.5636), and ECM331
(orf19.4255).
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